From the age of 12 years and over for residents of the European Union

Pfizer is seeking European approval to give its vaccine to children

The European Medicines Agency is studying a proposal by the pharmaceutical companies, "Pfizer" and "Biontech", to allow the use of their jointly produced anti-Coronavirus vaccine for children aged 12 years and over who are residents of the European Union.

The European Medicines Agency said it would conduct a "rapid assessment" of the data from the two companies and it is expected to release the results of its review in June, although it said that the timeframe could change if additional information is needed.

The Pfizer / Biontech vaccine has been approved in the European Union, but only for people 16 years and over.

And any medicine can have a different effect on minors than it does on adults.

This vaccine was developed based on technology that was not previously used to produce drugs for humans. 

The two companies said last month that they would request a permit to expand the use of the vaccine.

A similar proposal has been submitted to the US Drug Regulatory Authority.

The two companies say that the vaccine is 100 percent effective in preventing infection in the age group of 12 to 15 years, according to a clinical trial.

In the event that the European Medicines Agency recommends the use of the vaccine for new age groups, approval by the European Commission is still required, but this step is generally considered cosmetic.

Follow our latest local and sports news, and the latest political and economic developments via Google news